Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Fitzel R, et al. Among authors: lengerke c. Neoplasia. 2023 Jul;41:100902. doi: 10.1016/j.neo.2023.100902. Epub 2023 May 4. Neoplasia. 2023. PMID: 37148657 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: lengerke c. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.
Schumacher M, Beer S, Moraes Ribeiro E, Korkmaz F, Keppeler H, Fitzel R, Erkner E, Radszuweit P, Lengerke C, Schneidawind C, Hoefert S, Mauz PS, Schneidawind D. Schumacher M, et al. Among authors: lengerke c. Front Oncol. 2024 Mar 7;14:1333640. doi: 10.3389/fonc.2024.1333640. eCollection 2024. Front Oncol. 2024. PMID: 38515578 Free PMC article.
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk DJ, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker SY, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek HS, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G. Renovanz M, et al. Among authors: lengerke c. Neurooncol Adv. 2023 Feb 14;5(1):vdad012. doi: 10.1093/noajnl/vdad012. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 36915613 Free PMC article.
144 results